

Breast Cancer Pathways: Neoadjuvant and Adjuvant (Non-Hormonal)

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: _____

ICD-10 Code: _____

Biomarkers/Characteristics: (Select all that apply)

Hormone Receptor (ER or PR): Negative Positive

OncotypeDx: Low Intermediate High Not Done/Reported

HER2 status: Negative Positive Equivocal

Include ovarian suppression (pre-menopause only): Yes No

Neoadjuvant Therapy

- HER2 Positive, Stages IB through IIIC
 - TCH+P:** docetaxel (Taxotere), carboplatin, trastuzumab, and pertuzumab (Perjeta)
- HER2 Negative, Hormone Receptor (ER or PR) Positive, High risk for recurrence†
 - ddAC → weekly T:** dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel
 - TC:** docetaxel (Taxotere) and cyclophosphamide
- Triple Negative Breast Cancer (ER and PR, HER2 negative)
 - Pembrolizumab, carboplatin, and paclitaxel
 - Pembrolizumab, doxorubicin, and cyclophosphamide

Adjuvant Therapy

- HER2 Positive
 - Stages IA and IB
 - TH*:** paclitaxel and trastuzumab
 - Residual Disease following Neoadjuvant Therapy
 - Ado-trastuzumab emtansine (Kadcyla)
- HER2 negative, Hormone Receptor (ER or PR) Positive, High risk for recurrence†
 - ddAC à weekly T:** dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel
 - TC:** docetaxel (Taxotere) and cyclophosphamide
- Triple Negative Breast Cancer (ER, PR, and HER2 negative)
 - Continuation following Neoadjuvant Therapy
 - Pembrolizumab, following neoadjuvant pembrolizumab-based treatment
 - Residual Disease following Neoadjuvant Therapy
 - Capecitabine

* Administration of trastuzumab is limited to 1 year (maximum 18 cycles)

† Prognostic stage II-IIIC, OncotypeDx high risk

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631

Last review: 11/1/2022 | Effective date: 1/16/2023

© 2023 Carelon Medical Benefits Management